Immunovant receives $200M investment from Roivant at 15% premium to VWAP

Immunovant, Inc.

Roivant purchases 17,021,276 shares at $11.75/share ($200M gross proceeds), a 15% premium to 20-day VWAP.
Roivant's ownership increases from 57.5% to 63.8%; Immunovant pro forma cash ~$600M.
Proceeds to fund development of IMVT-1401; pivotal trial for myasthenia gravis planned within 12 months.
Dr. Frank Torti appointed Executive Chairperson, effective immediately, no additional compensation.
Investment approved by special committee of independent directors.

item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Frank M. Torti

Executive Chairperson

IMVT · Immunovant, Inc.

Effective: 2021-08-02
Filed: August 2, 2021, 7:59 PM ET

Effective August 2, 2021, Dr. Frank M. Torti, age 42, Immunovant’s current Chairperson, was appointed Executive Chairperson.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Frank M. Torti was appointed as Executive Chairperson at Immunovant, Inc..

Action: appointed
Role: Executive Chairperson

Exact text from the filing

Effective August 2, 2021, Dr. Frank M. Torti, age 42, Immunovant’s current Chairperson, was appointed Executive Chairperson.

View on SEC.gov

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-21-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.